Behind the economic data in July: who helps pharmaceutical companies "stand up"?

[market analysis of pharmaceutical network] on August 14, the National Bureau of statistics released the operation data of national economy in July The growth rate of some economic data fell to a certain extent, but the overall operation was in a reasonable range and continued to develop steadily In terms of manufacturing industry, the added value of high-tech manufacturing industry in July increased by 6.6% year-on-year, 1.8 percentage points faster than that of industries above Designated Size nationwide From January to July, investment in high-tech manufacturing industry and high-tech service industry (up 11.1% and 11.9% respectively on a year-on-year basis) grew faster than the total investment by 5.4 and 6.2 percentage points respectively In addition, in terms of the number of enterprises, the daily average number of new registered enterprises reached 21300 in July, which continued to increase And the profit growth rate of enterprises in the first half of this year is obviously faster than the overall profit rate level The industry said that behind these data, it is inseparable from "tax reduction and fee reduction", as well as continuous optimization of the general environment, good market competition environment and other factors In terms of the tax reduction and fee reduction policies implemented this year, the survey results show that 52.2% of enterprises in the second quarter thought that they enjoyed the dividend of tax reduction and fee reduction, which increased 3 percentage points compared with the first quarter, and continued to rise for six quarters It can be seen that the benefits it brings to enterprises are solid, from which enterprises can obtain the power of innovation and stimulate innovation vitality Among them, there are many enterprises in the pharmaceutical industry and pharmaceutical equipment field For example, some pharmaceutical companies received more than 31 million yuan of tax refunds in only three days The company has two sources of funds, one is its own funds and the other is loans from banks, the company said At a critical moment, the VAT tax rebate policy at the end of the period solves the urgent need of the company, and also allows the enterprise to have more funds to invest in research and development Also, pharmaceutical companies said that in 2018, thanks to the preferential treatment and support of R & D expenses plus deduction and high-tech enterprise income tax, the vitality and enthusiasm of enterprise innovation continued to improve "The high-tech enterprise income tax preferential policy has reduced and exempted the enterprise income tax by 280 million yuan in total, and the R & D expense plus deduction has reduced and exempted the enterprise income tax by more than 23 million yuan in total With the implementation of the tax reduction and fee reduction policy, it will bring more benefits to enterprises " In the pharmaceutical equipment industry, some pharmaceutical equipment enterprises said that under the influence of tax reduction and fee reduction, some of the funds saved by the enterprises were used to improve the production and life of employees, and the other part was used for investment in technological transformation, new product research and development, scientific and technological innovation, to build the core competitiveness of the enterprises In addition, pharmaceutical equipment enterprises seize the opportunity and solve technical problems in tax reduction and fee reduction The company said it has been trying to upgrade its product line in the fierce market competition of increasing product homogeneity and industry concentration "This year's VAT rate will be lowered We intend to continue to use the saved tax for technological innovation of products and R & D of new equipment, so as to accelerate the pace of transformation and upgrading of enterprises to a greater extent." The industry believes that the shuffling of pharmaceutical equipment market is intensifying In the process of competing for success, pharmaceutical equipment enterprises with strength need relevant support, and small and medium-sized pharmaceutical equipment enterprises also need more practical help In general, at present, the tax cuts and bonuses are wave after wave These enterprises that have won the "red envelope" will accelerate the transformation and upgrading, while the sense of access of the market main body will become more and more strong, which is conducive to promoting the better development of the whole industry.